αl-Antitrypsin Deficiency: An Overview

References

• Vaughan L, Lorier MA, Carrell RW. al-Antitrypsin microheterogeneity: isolation and Physiological significance of isoforms. Biochim Biophys Acta. 1982; 701: 339–45.
   Google Scholar
• Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1 -Antitrypsin deficiency Am J Med. 1988; 84 (Suppl 6A): 13–31.
   Google Scholar
• Crystal RG, Brantly ML, Hubbard RC, Curiel DT, States DJ, Holmes MD. The al-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest. 1989; 95:196–208.
   Google Scholar
• Carrell RW.al-Antitrypsin: molecularpathology, leucocytes, and tissue damage. J Clin Invest. 1986; 78:1427–31.
   Google Scholar
• Perlmutter DH. The cellular basis for liver injury in a 1-Antitrypsin deficiency. Hepatology. 1991; 13: 172–85.
   Google Scholar
• Perlmutter DH, Pierce JA. The a 1-Antitrypsin gene and emphysema. Am J Physiol. 1989; 257: LI 47–62.
   Google Scholar
• Carrell RW, Jeppsson J-O, Laurell C-B, et al. Structure and variation of human al-Antitrypsin. Nature. 1982; 298: 329–34.
   Google Scholar
• Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin: al. Antitrypsin Pittsburgh (358Met-Arg), a fatal bleeding disorder. N Engl J Med. 1983; 309: 6948.
   Google Scholar
• Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for al-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987; 316: 1055–62.
   Google Scholar
• Wewers MD, Casolaro MA, Crystal RG. Comparison of alpha-l-Antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-l-antitrypsin phenotype null-null before and during alpha-l-antitrypsin augmentation therapy. Am Rev Resp Dis. 1987; 135: 539–43.
   Google Scholar
• Laurell C-B, Eriksson S. The electrophoretic αl-globulin pattern of serum in al-Antitrypsin deficiency. Scand J Clin 1Mb Invest. 1963; 15: 132–40.
   Google Scholar
• Perlmutter DH, May LT, Sehgal PB. Interferon 62/interleukin 6 modulates synthesis of al. Antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest. 1989; 84: 138–44.
   Google Scholar
• Carlson J, Eriksson S. al-Antitrypsin and other acute phase reactants in liver disease. Acta Med Scand. 1980; 207: 79–83.
   Google Scholar
• Laurell C-B, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy and estrogens. J Clin Endocrinol Metab. 1979; 49: 719–25.
   Google Scholar
• Rothman JE. Polypeptide chain binding proteins: catalysts of protein folding and related processes in cells. Cell. 1989; 59: 591–601.
   Google Scholar
• Mornex J-F, Chytil-Weir A, Martinet Y, Courtney M, LeCocq J-P, Crystal RG. Expression of the alpha-l-antitrypsin gene in mononuclear phagocytes of normal and alpha-l-antitrypsin deficient individuals. J Clin Invest. 1986; 77: 1952–61.
   Google Scholar
• Perlmutter DH, Kay RM, Cole FS, Rossing TH, Van Thiel D, Colten HR. The cellular defect in αl-proteinase inhibitor (a 1 -PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA. Proc Natl Acad SciUSA. 1985;82:6918–21.
   Google Scholar
• Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on hepatoma cells and human monocytes. Proc Natl Acad Sci USA. 1990; 87: 3753–57.
   Google Scholar
• Perlmutter DH, Travis J, Punsal PI. Elastase regulates the synthesis of its inhibitor, a 1-proteinase inhibitor, and exaggerates the defect in homozygous Pi ZZ a 1 PI deficiency. J Clin Invest. 1988; 81:1774–80.
   Google Scholar
• Perlmutter DH, Joslin G, Nelson P, Schasteen C, Adams SP, Fallon RJ. Endocytosis and degradation of al-Antitrypsin protease complexes is mediated by the serpin-enzyme complex (SEC) receptor. J BiolChem. 1990; 265: 16713–16.
   Google Scholar
• Carlson JA, Rogers BB, Sifers RN, Hawkins HK, Finegold MJ, Woo SLC. Multiple tissues express al-Antitrypsin in transgenic mice and man. J Clin Invest. 1988; 82: 26–36.
   Google Scholar
• Koopman P, Povey S, Lovell-Badge RH. Widespread expression of human al-Antitrypsin in transgenic mice revealed by in situ hybridization. Genes Dev. 1989; 3: 16–25.
   Google Scholar
• Hubbard RC, Crystal RG. Alpha-1-Antitrypsin augmentation therapy for alpha-l-antitrypsin deficiency. Am J Med. 1988; 84 (Suppl 6A): 52–62.
   Google Scholar
• Gadek JE, Fells GA, Zimmerman RL, Rennard SI, Crystal RG. Anti-elastases of the human alveolar structures. Implications fortheproteaseantiprotease theory of emphysema. J Clin Invest. 1981; 68: 889–98.
   Google Scholar
• Wewers M. Pathogenesis of emphysema. Assessment of basic science concepts through clinical investigation. Chest. 1989; 95:190–5.
   Google Scholar
• The pathogenesis of pulmonary emphysema. Lancet. 1980; I: 743–5.
   Google Scholar
• Janoff A. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Resp Dis. 1985; 132: 417–33.
   Google Scholar
• Travis J. Structure, function, and control of neutrophil proteinases. Am J Med. 1988; 84(Supp 6A): 37–42.
   Google Scholar
• Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science. 1979; 206: 1315–16.
   Google Scholar
• Johnson D, Travis J. The oxidative inactivation of human a-l-Proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chert 1979; 254: 4022–26.
   Google Scholar
• Carp H, Janoff A. Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. Am Rev Resp Dis. 1978; 118:617–21.
   Google Scholar
• Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanisms of emphysema: al-Proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad SO USA. 1982;79:2041–45.
   Google Scholar
• Carp H, Janoff A. In vitro suppression of serum elastase-inhibitory capacity by reactive oxyge” species generated by phagocytosing polymorphonuclear leucocytes. J Clin Invest. 1979; 63; 793–7.
   Google Scholar
• Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev ResP Dis. 1983; 128: 833–9.
   Google Scholar
• Damiano VV, Tsang A, Kucich U, et al. Immunolocalization of elastase in hurna” emphysematous lungs. J Clin Invest. 1986; 78482–93.
   Google Scholar
• Weitz JI, Crowley KA, Landman SL, Lipman BI, Yu J. Increased neutrophil elastase activity cigarette smokers. Ann Intern Med. 1987; 107:680–2.
   Google Scholar
• Niewoehner de, Kleinerman J, Rice DB Pathologic changes in the peripheral airways °f young cigarette smokers. N Engl J Med. 1974; 291:755–8.
   Google Scholar
• Lieberman J. Alphal-antitrypsin deficiency and related disorders. In: Emery AEH, Rimoin DF eds. Principles and Practice of Medical Genetics-Edinburgh: Churchill-Livingstone. 1983:911–35
   Google Scholar
• Larsson C. Natural history and life expectancy severe al-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978; 204: 345–51.
   Google Scholar
• Long GL, Chandra T, Woo SLC, Davie EW, Kurachi K. Complete nucleotide sequence of the cDNA for human c al-antitrypsin and the gene for the S variant. Biochemistry. 1984; 23: 4828–37.
   Google Scholar
• Perlino E, Cortese R, Ciliberto G. The human αl-antitrypsin gene is transcribed from two different promotors in macrophages and hepatocytes. EM BO J. 1987; 6: 2767–71.
   Google Scholar
• Fagerhol MK, Laurell C-B. The polymorphism of «prealbuniins» and al-antitrypsin in human sera. Clin Chim Acta. 1967; 16:199–203.
   Google Scholar
• Fagerhol MK, Cox DW. The Pi polymorphism: genetic, biochemical, and clinical aspects of human al-antitrypsin. Adv Hum Genet. 1981; 11:1 -62.
   Google Scholar
• Gadek JE, Crystal RG. al-antitrypsin deficiency. In: Stanbury JB, Wijngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. Metabolic Basis of Inherited Disease. New York: McGraw Hill. 1982:1450–67.
   Google Scholar
• Keuppers F, Black LF. al-Antitrypsin and its deficiency. Am Rev Resp Dis.1974; 110: 176–94.
   Google Scholar
• Cox DW, Johnson AM, Fagerhol MK. Report of nomenclature meeting for al-antitrypsin. Hum Genet. 1980; 53: 429–33.
   Google Scholar
• Nukiwa T, Brantly M, Ogushi F, et al. Characterization of the M1 (Ala 213) type of αl-antitrypsin, a newly recognized common «normal» al-antitrypsin haplotype. Biochemistry. 1987; 26: 5259–67.
   Google Scholar
• Nukiwa T, Brantly ML, Ogushi F, Fells GA, Crystal RG. Characterization of the gene and protein of the common al-antitrypsin normal M2 allele. Am J Hum Genet. 1988; 44: 322–30.
   Google Scholar
• Bamforth FJ, Kalsheker NA. al-antitrypsin deficiency due to Pi null: clinical presentation and evidence for molecular heterogeneity. J Med Genet. 1988; 25: 83–7.
   Google Scholar
• Nukiwa T, Takahashi H. Brantly M, Courtney M, Crystal RG. Alpha l antitrypsin Null granite falls, 3, a nonexpressing al -antitrypsin gene associated with a frameshift to stop mutation in a coding axon. J Biol Chem. 1987; 262: 1999–2004.
   Google Scholar
• Curiel D, Brantly M, Curiel E, Stier L, Crystal RG. al-Antitrypsin deficiency caused by the αl. Antitrypsin Null Mattawa gene. J Clin Invest. 1989; 83: 1144–52.
   Google Scholar
• Jones EA, Vergalla J, Skeer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated al-antitrypsin. Clin Sci Mot Med. 1978; 55: 139–48.
   Google Scholar
• Makino S, Reed CE. Distribution and elimination of exogenous al-antitrypsin. J Lab Clin Med. 1970; 75:742–6.
   Google Scholar
• Laurell C-B, Nosslin B, Jeppsson J-O. Catabolic rate of al-antitrypsin of Pi type M and Z in man. Clin Sci Mol Med. 1977; 52: 457–61.
   Google Scholar
• Hercz A, Harpaz N. Characterization of the oligosaccharides of liverZ variant al -antitrypsin. Canad J Biochem. 1980;58:644–8.
   Google Scholar
• Bathurst IC, Travis J, George PM, Carrell RW. Structural and functional characterization of the abnormal Z al-antitrypsin isolated from human liver. FEBSLett. 1984; 177: 179–83.
   Google Scholar
• Foreman RC, Judah JD, Colman A. Xenopus oocytes can synthesize but do not secrete the Z variant of human a 1 -antitrypsin. FEBSLett. 1984; 168:84–8.
   Google Scholar
• Verbanac KM, Heath EC. Biosynthesis, processing, and secretion of M and Z variant human αl-antitrypsin. J Biol Chem. 1986; 261: 9979–89.
   Google Scholar
• Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha l-antitrypsin accumulation in the liver. Nature. 1992; 357: 605–7.
   Google Scholar
• Glaser CB, Karic L, Fallat RJ, Stockert R. Alpha-l-antitrypsin. Plasma survival studies in the rat of the normal and homozygote deficient forms. Biochim Biophys Acta. 1977; 495: 87–92.
   Google Scholar
• Callea F, Fevery J, Massi G, Lievens C, De Groote J, Desmet VJ. Alpha-1-antitrypsin (AAT) and its stimulation in the liver of Pi MZ phenotype individuals: a «recruitment-secretory block» («RSB») phenomenon. Liver. 1984; 4: 325–37.
   Google Scholar
• Callea F. Immunohistochemical study on alpha-l-antitrypsin. Thesis. Leuven 1983.
   Google Scholar
• Feldman G, Bignon J, Chahinian P, Degott C, Benhamou J-P. Hepatocyte ultrastructural changes in al-antitrypsin deficiency. Gastroenterology. 1974; 67: 1214–24.
   Google Scholar
• Callea F, Brisigotti M, Faa G, Lucini L, Eriksson S. Identification of Pi Z gene products in liver tissue by a monoclonal antibody specific for the Z mutant of al-antitrypsin. J Hepatol. 1991; 12:3726.
   Google Scholar
• Carlson J, Eriksson S. Chronic “cryptogenic” liver disease and malignant hepatoma in intermediate alpha-l-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastro-enterol.1985; 20: 835–42.
   Google Scholar
• Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type a 1 -antitrypsin is less competent than Ml-type al-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987; 80:136674.
   Google Scholar
• Owen MC, Carrell RW, Brennan SO. The abnormality of the S variant of human al-antitrypsin. Biochem Biophys Acta. 1976; 453: 257–61.
   Google Scholar
• Crowley JJ, Sharp HL, Freier E, Ishak KG, Show P. Fatal liver disease associated with al-antitrypsin deficiency Pi M 1/Pi Mduane Gastroenterology. 1987; 93: 242–4.
   Google Scholar
• Reid CL, Wiener GJ, Cox DW, Richter JE, Geisinger KR. Diffuse hepatocellular dysplasia and carcinoma associated with the M malton, variant of αl-antitrypsin. Gastroenterology. 1987; 93: 181–7.
   Google Scholar
• Fabbretti G, Sergi C, Consales G, et al. Genetic variants of alpha-l-antitrypsin (AAT). Liver. 1992; 12: 296–301.
   Google Scholar
• Talamo RC, Langley CE, Reed CE, Makino S. Alpha-l-antitrypsin deficiency: a variant with no detectable a 1 -antitrypsin. Science. 1973; 181:70.
   Google Scholar
• Garver RI, Mornex J-P, Nukiwa T, et al. Alpha-l-antitrypsin deficiency and emphysema caused by homozygous inheritance of non expressing alpha-l-antitrypsin genes. N Engl J Med. 1986; 314: 762–6.
   Google Scholar
• Carlson JA, Rogers BB, Sifers RN, et al. Accumulation of Pi Z al-antitrypsin causes liver damage in transgenic mice. J Clin Invest. 1989; 83: 1183–90.
   Google Scholar
• Dycaico JM, Grant SGN, Felts K, et al. Neonatal hepatitis induced by al-antitrypsin: a transgenic mouse model. Science. 1988; 242:1409–12.
   Google Scholar
• Eriksson S. Studies in alpha-l-antitrypsin deficiency. ActaMedScand. 1965; 177(Suppl): 1–85.
   Google Scholar
• Sveger T. Liver disease in alpha-l-antitrypsin deficiency detected by screening of200,000 infants. N Engl J Med. 1976;294:1316–21.
   Google Scholar
• Kimpen J, Bosnians E, Hermans R, Raus J. Kwantitatieve bepaling van alfa-I-antitrypsine in navelstrengbloed om afwijkende fenotypes op te sporen. T Geneesk. 1986; 42: 417–22 (in Dutch).
   Google Scholar
• Dykman JH, PendersTJ, Kramps J A, Sonderkamp HJA, Van den Broek WGM, ter Haar BGA. Epidemiology of alpha-l-antitrypsin deficiency in the Netherlands. Hum Genet. 1980; 53:409–13.
   Google Scholar
• Cook PJL. The genetics of alpha l-antitrypsin: a family study in England and Scotland. Ann Hum Genet. 1975; 38: 275–87.
   Google Scholar
• Blundell G, Frazer A, Cole RB, Nevins NC. Alpha-l-antitrypsin phenotypes in Northern Ireland. Ann Hum Genet. 1975; 38: 289–94.
   Google Scholar
• Arnaud P, Galbraith RM, Faulk WP, Black C. Pi phenotypes of alpha-l-antitrypsin in Southern England: identification of M subtypes and implications for genetic studies. Clin Genet. 1979;l5: 406–10.
   Google Scholar
• Hutchison DCS. Natural history of alpha-1-protease inhibitor deficiency. Am J Med. 1988; 84 (Suppl 6A): 3–12.
   Google Scholar
• Tobin MJ, Cook PJL, Hutchison DCS. Alpha-l-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z: a survey of the British Thoracic Association. Br J Dis Chest 1983;77:14–27.
   Google Scholar
• Eriksson S. Pulmonary emphysema and alpha-l-antitrypsin deficiency. ActaMedScand. 1964; 175. 197–205.
   Google Scholar
• Larsson C, Dirksen H, Sundstrom G, Eriksson αl-Lungfunction studies in asymptomatic individuals with moderately (Pi SZ) and severely (Pi Z) reduced levels of al-antitrypsin. Scand J Resp Dis. 1976; 57: 267–80.
   Google Scholar
• Hutchison DCS, Tobin MJ, Cook PJL. Alpha-l-antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. Br J Dis Chest. 1983; 77: 28–34.
   Google Scholar
• Morse JO. Alpha-1 antitrypsin deficiency (second of two parts). N Engl J Med. 1978; 299:1099–10588.
   Google Scholar
• Lieberman J, Winter B, Sastre A. Alpha-l-antitrypsin Pi-types in 965 COPD patients. Chest- 1986; 89: 370–3.
   Google Scholar
• Bartman K, Fooke-Achterrath M, Koch G, et al. Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD). Eur J Resp Dis. 1985; 66: 284–96.
   Google Scholar
• Eriksson S, Lindell S-E, Wiberg R. Effects of smoking and intermediate a I -antitrypsin deficiency (Pi MZ)on lungfunction. Eur J Resp Dis. 1985; 67: 279–85.
   Google Scholar
• Bruce RM, Cohen BH, Diamond EL, et αl-Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects. Am Rev Resp Dis- 1984;130:386–90.
   Google Scholar
• Buist AS, Sexton GJ, Azzam A-MH, Adams BE. Pulmonary function in heterozygotes for alpha li antitrypsin deficiency: a case-control study. Am Rev Resp Dis. 1979; 120: 759–66.
   Google Scholar
• McDonagh DJ, NathanSP, KnudsonRJ, Lebowitz MD. Assessment of alpha-l-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. J Clin Invest. 1979; 63: 299–309.
   Google Scholar
• Vance JC, Hall WJ, Schwartz RH, Hyde RW, Roghmann KJ, Mudholkar GC. Heterozygous alpha-l-antritypsin deficiency and respiratory function in children. Pediatrics. 1977; 60: 26372.
   Google Scholar
• Hall WJ, Hyde RW, Schwartz RH, et al. Pulmonary abnormalities in intermediate alpha-l-antitrypsin deficiency. J Clin Invest. 1976; 58: 1069–77.
   Google Scholar
• Laros KD, Biemond J, Klasen EC. The faccid lung syndrome and a 1-protease inhibitor deficiency. Chest. 1988;93:831–5.
   Google Scholar
• Larsson C, Eriksson S, Dirksen H. Smoking and intermediate alpha-l-antitrypsin deficiency and lung function in middle-aged men. Br Med J. 1977; 2: 922–5.
   Google Scholar
• Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-l-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med. 1969; 73: 934–9.
   Google Scholar
• Aagenaes O, Matlary A, Elgjo K, Munthe E, Fagerhol M. Neonatal cholestasis in alpha-l-antitrypsin deficient children. Acta Paediatr Scand. 1972; 61: 632–42.
   Google Scholar
• Moroz SP, Cutz E, Cox DW, Sass-Kortsak A. Liver disease associated with alpha-l-antitrypsin deficiency in childhood. J Pediatr. 1976; 88:1925.
   Google Scholar
• Porter C A, Mowat AP, Cook PJL, Hay nes DWG, Shilkin KB, Williams R. al-antitrypsin deficiency and neonatal hepatitis. Br Med J. 1972; 3: 435–9.
   Google Scholar
• Psacharopoulos HT, Mowat AP, Cook PJL, Carlile PA, Portmann B, Rodeck CH. Outcome of liver disease associated with a 1 -antitrypsin deficiency (Pi Z). Arch Dis Child. 1983; 58: 882–7.
   Google Scholar
• Sveger T. al-antitrypsin deficiency in early childhood. Pediatrics. 1978; 62: 22–5.
   Google Scholar
• S veger T. The natural history of liver disease in a 1-antitrypsin deficient children. Acta Paediatr Scand. 1988; 77: 847–51.
   Google Scholar
• Deutsch J, Becker H, Dubs R, et al. Leberer-krankungen bei Kindern und deren Verwandten mit homozygoten und heterozygoten Alpha-1 Antitrypsin Mangel. Wiener Klin Wchschr.\987; 99: 84–91.
   Google Scholar
• Ghisham FK, Greene HL. Liver disease in children with PiZZ αl-antitrypsin deficiency. Hepatology. 1988;8:307–10.
   Google Scholar
• Hadchouel M, Gautier M. Histopathologic study of the liver in the early cholestatic phase of alpha-l-antitrypsin deficiency. J Pediatr. 1976; 89: 21115.
   Google Scholar
• Strobe I S, Bender SW, Posselt H-G, Hubner K. Alpha-l-antitrypsin deficiency: fulminant course in early infancy. Helv Paediatr Acta. 1980; 35: 75–83.
   Google Scholar
• Udall JN, Dixon M, Newman AP, Wright JA, James B, Bloch KJ. Liver disease in a 1 -antitrypsin deficiency. A retrospective analysis of the influence of early breast vs bottle feeding. JAMA. 1985; 253: 2679–82.
   Google Scholar
• Sveger T. Breast feeding, al-antitrypsin deficiency, and liver disease ? JAMA. 1985; 254: 3036.
   Google Scholar
• Wilkinson EJ, Raab K, Browning CA, Hosty TA. Familial hepatic cirrhosis in infants associated with alpha-1 -antitrypsin SZ phenotype. J Pediatr. 1974; 85: 159–64.
   Google Scholar
• Roberts PF. Pi ZZ alpha-1 -antitrypsin deficiency in a 20-week fetus. Hum Pathol.m5\ 16: 18890.
   Google Scholar
• Dorney SFA, Hassall EG, Arbuckle SM, Vargas JH, Berquist WE. SZ phenotype alpha-l-antitrypsin deficiency with paucity of the interlobular bile ducts. Aust Paediatr J. 1987; 23: 55–6.
   Google Scholar
• Christen H, Bau J, Halsband H. Hereditary alpha-l-antitrypsin deficiency associated with congenital extrahepatic bile duct hypoplasia. Klin Wsclir. 1975;53:90–9.
   Google Scholar
• Nord KS, Saad S, Joshi VV, McLaughlin LC. Concurrence of al-antitrypsin deficiency and biliary atresia. J Pediatr. 1987; 111: 416–18.
   Google Scholar
• Vandenplas Y, Franckx J, Liebaers I, Ketelbant P, Sacre L. Neonatal hepatitis with obstructive jaundice in an SZ heterozygous alpha l antitrypsin-deficient boy and destructive lung disease in his SZ mother. Eur J Pediatr. 1985; 144:391–4.
   Google Scholar
• Hope PL, Hall MA, Millward-Sadler GH, Normand KS. Alpha-l-antitrypsin deficiency presenting as a bleeding diathesis in the newborn. Arch Dis Child. 1982; 57: 68–70.
   Google Scholar
• Rosenthal Ph, Liebmann WM, Thaler MM. Alpha-l-antitrypsin deficiency and severe infantile liver disease. Am J Dis Child. 1979; 133: 1195–6.
   Google Scholar
• Pittschieler K, Massi G. Liver involvement in infants with Pi SZ phenotype of al-antitrypsin deficiency. J Pediatr Gastroenterol Nutr. 1992; 15: 315–8.
   Google Scholar
• Kidd VJ, Golbus MS, Wallace RB, Itakura K, Woo SLC. Prenatal diagnosis of al-antitrypsin deficiency by direct analysis of the mutation site in the gene. N Engl J Med. 1984; 310: 639–42.
   Google Scholar
• Hejtmancik JF, Sifers RN, Ward PA, Harris S, Mansfield T, Cox DW. Prenatal diagnosis of αl-antitrypsin deficiency by restriction fragment length polymorphism, and comparison with oligonucleotide probe analysis. Lancet. 1986; 2: 767–70.
   Google Scholar
• Nukiwa T, Brantly M, Garver R, et al. Evaluation of «at risk» alpha l antitrypsin genotype SZ with synthetic oligonucleotide gene probes. J Clin Invest. 1986; 77: 528–37.
   Google Scholar
• Newton CR, Kalsheker N, Graham A, et al. Diagnosis of alpha -1-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products. Nucleic Acids Res. 1988; 16: 8233–43.
   Google Scholar
• Triger DR, Millward-Sadler GH, Czaykowski AA, Trowell J, Wright R. Alpha-l-antitrypsin deficiency and liver disease in adults. Q J Med. 1976; 45: 351–72.
   Google Scholar
• Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency. N Engl J Med. 1986; 314: 736–9.
   Google Scholar
• Eriksson S. al-antitrypsin deficiency and liver cirrhosis in adults. Acta Med Scand. 1987; 221: 461–7.
   Google Scholar
• Cox DW, Smyth S. Risk for liver disease in adults with alpha-l-antitrypsin deficiency. Am J Med. 1983;74:221–7.
   Google Scholar
• Rakela J, Goldschmiedt M, Ludwig J. Late manifestations of chronic liver disease in adults with alpha-l-antitrypsin deficiency. Dig Dis Sci. 1987; 32: 1358–62.
   Google Scholar
• Hodges JR, Millward-Sadler GH, Barbatis C, Wright R. HeterozygousMZalpha-l-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med.\9&\\ 304: 557–60.
   Google Scholar
• Eriksson S. Liver disease and intermediate αl-antitrypsin deficiency. Acta Med Scand. 1981; 210: 241–14.
   Google Scholar
• Marwick TH, Cooney PT, Kerlin P. Cirrhosis and hepatocellular carcinoma in a patient with heterozygous (MZ) alpha-1-antitrypsin deficiency. Pathology. 1985; 17: 649–52.
   Google Scholar
• Rawlings W, Moss J, Cooper HS, Hamilton SR. Hepatocellular carcinoma and partial deficiency of alpha-l-antitrypsin (MZ). Ann Intern Med. 1974;81:771–73.
   Google Scholar
• Chan CH, Steer CJ, Vergalla J, Jones EA. Alpha-l-antitrypsin deficiency with cirrhosis associated with the protease inhibitor phenotype SZ. Am J Med. 1978;65:978–84.
   Google Scholar
• Palmer PE, Gherardi GJ, Baldwin JM, Wolfe HJ. Adult liver disease in SZ phenotype alpha-l-antitrypsin deficiency. Ann Intern Med. 1978; 88: 59–60.
   Google Scholar
• Lieberman J, Silton RM, AgliozzoCM, McMahon J.Hepatocellular carcinoma and intermediateal-antitrypsin deficiency (MZ phenotype). Am J Clin Pathol. 1975; 64: 304–10.
   Google Scholar
• Gadek JE, Fulmer JD, Gelfand J A, Frank MM, Petty TL, Crystal RG. Danazol-induced augmentation of serum al-antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest. 1980; 66: 82–7.
   Google Scholar
• Eriksson S. The effects of tamoxifen in intermediate alpha l-antitrypsin deficiency associated with the phenotype Pi SZ. Ann Clin Res. 1983; 15: 95–8.
   Google Scholar
• Wewers MD, Gadek JE, Koegh BA, Fells GA. Crystal RG. Evaluation of danazol therapy for patients with Pi ZZ al -antitrypsin deficiency. A Rev Respin Dis. 1986; 134: 476–80.
   Google Scholar
• Wewers MD, Brantly ML, Casolaro MA, Crystal RG. Evaluation of Tamoxifen as a therapy to augment alpha-l-antitrypsin concentrations in 1 homozygous alpha-l-antitrypsin deficient subjects. Am Rev Resp Dis. 1987; 135:401–2.
   Google Scholar
• Gadek JE, Klein HG, Holland PV, Crystal RG.-Replacement therapy of alpha-l-antitrypsin deficiency. J Clin Invest. 1981; 68:1158–65.
   Google Scholar
• Schmidt EW, Rasche B, Ulmer WT, et al. Replacement therapy for alpha-1-protease inhibitor deficiency in Pi Z subjects with chronic obstructive lung disease. Am J Med. 1988; 84(Suppl 6A): 639.
   Google Scholar
• Gillissen A, Schmidt EW, Rasche B, Ulmer WT-Biochemical reaction of alpha-1 -antitrypsin during the substitution therapy of patients with homozygote Pi-ZZ deficit. Klin Wschr. 1989; 67: 328–35.
   Google Scholar
• Hubbard RC, Sellers S, Czerski D, Stephens L< Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for al-antitrypsin deficiency. JAMA. 1988; 260:1259–64.
   Google Scholar
• Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Antineutrophil-elastase defenses of the lower respiratory tract in al-antitrypsin deficiency directly augmented with an aerosol of al-antitrypsin. Ann Int Med. 1989; 111: 206–12.
   Google Scholar
• Banda MJ, Rice AG, Griffin GL, Senior RM. αl-Proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. J Biol Chem. 1988; 263: 4481–84.
   Google Scholar
• Banda M J, Rice AG, Griffin GL, Senior RM. The inhibitory complex of human a 1-proteinase inhibitor and human leucocyte elastase is a neutrophil chemoattractant. J Exp Med. 1988; 167: 1608–15.
   Google Scholar
• Rosenberg S, Barr PJ, Najarian RC, Hallewell RA. Synthesis in yeast of a functional oxidation-resistant mutant of human a 1 -antitrypsin. Nature. 1984; 312: 77–80.
   Google Scholar
• Doherty JB, Ashe BM, Argenbright LW, et al. Cephalosporin antibiotics can be modified to inhibit human leucocyte elastase. Nature. 1986; 322:192–4.
   Google Scholar
• Bonney RJ, Ashe B, Maycock A, et al. The pharmacological profile of the substituted beta-lactam, L-659,286: a member of a new class of human PMN elastase inhibitors. J Cell Biochem 1988;39:47–53.
   Google Scholar
• Fletcher DS, Osinga DG, Hand KM, et al. A comparison of al-proteinase inhibitor Methoxy succinyl-Ala-Ala-Pro-Val-Chloromethylketone and specific B-Lactam inhibitors in an acute model of human polymorphonuclear leucocyte elastase-induced lung hemorrhage in the hamster. Am Rev RespDis. 1990; 141: 672–7.
   Google Scholar
• Hood JM, Koep LJ, Peters RL, et al. Liver transplantation for advanced liver disease with alpha-1-antitrypsin deficiency. N Engl J Med. 1980; 302: 272–4.
   Google Scholar
• Esquivel CO, Vicente E, Van Thiel D, et al. Orthotopic liver transplantation for alpha-l-antitrypsin deficiency: an experience in 29 children and ten adults. TransplProc. 1987; 29:3798–802.
   Google Scholar
• Van Furth R, Kramps J A, Van der Putten ABMM, Krom RAF, Gips CH. Change in al-antitrypsin phenotype after orthotopic liver transplant. Clin Exp Immunol. 1986; 66: 669–72.
   Google Scholar
• Starzl TL, Porter KA, Busuttil RW, Pichlmayr R. Portocaval shunt in three children with alpha l-antitrypsin deficiency and cirrhosis: 9–12 1/2 years later. Hepatology. I990;l 1:152–4.
   Google Scholar